Everyone seems delighted about the news about the vaccine. What’s the good news?AstraZeneca and Oxford experimented with two different dosing regimens.
One regimen demonstrated an efficacy of 90% when AZD1222 was given as a half dose followed by a full dose one month later. The second regimen showed 62% efficacy when given as two full doses a month apart.
The average efficacy: 70%.So what now?While the trials continue, including the search for an explanation as to why the lower dosage was better, the results allow AstraZeneca and the Serum Institute to approach drug regulators for emergency licensure.
The question of how long the immunity would last after the vaccine is administered is yet to be answered.Why does this vaccine matter more.